FDA Approves Blinatumomab for 72- and 96-Hour Infusion Durations
On December 17, the US Food and Drug Administration approved blinatumomab for 72- and 96-hour infusion durations to offer more flexibility for physicians and their patients.
In Person Conference & ConventionJuly 18, 2026 at 3:30 PM CDT5005 Glumack Drive, Minneapolis, MN, USAInterContinental Hotel Minneapolis – St. Paul Airport, Minneapolis
In Person Conference & ConventionAugust 12, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI 96825, USARoy's Restaurants – Hawaii Kai, Honolulu
LOS 2026 Cancer Congress - National Oncology Updates
In Person Conference & ConventionAugust 14, 2026 at 11:00 AM CDT859 Convention Center Blvd, New Orleans, LA, USANew Orleans Marriott Warehouse Art District, New Orleans
